Therapy of highly active pediatric multiple sclerosis.
Mult Scler
; 25(1): 72-80, 2019 01.
Article
in En
| MEDLINE
| ID: mdl-28933245
ABSTRACT
OBJECTIVE:
Study aims were to determine the frequency of highly active disease in pediatric multiple sclerosis (MS), the response to natalizumab (NTZ) and fingolimod (FTY) treatment, and the impact of current treatment modalities on the clinical course.METHODS:
Retrospective single-center study in the German Center for MS in Childhood and Adolescence.RESULTS:
Of 144 patients with first MS manifestation between 2011 and 2015, 41.6% fulfilled the criteria for highly active MS. In total, 55 patients treated with NTZ and 23 with FTY demonstrated a significant reduction in relapse rate (NTZ 95.2%, FTY 75%), new T2 lesions (NTZ 97%, FTY 81%), and contrast-enhancing lesions (NTZ 97%, FTY 93%). However, seven patients switched from NTZ to FTY experienced an increase in disease activity. Comparing pediatric MS patients treated in 2005 with those treated in 2015 showed a 46% reduction in relapse rate and a 44% reduction in mean Expanded Disability Status Scale (EDSS).CONCLUSION:
The rate of highly active disease among pediatric MS patients is high; more than 40% in our cohort. Response to NTZ and FTY treatment is similar if not better than observed in adults. Current treatment modalities including earlier treatment initiation and the introduction of NTZ and FTY have significantly improved the clinical course of pediatric MS.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Outcome Assessment, Health Care
/
Fingolimod Hydrochloride
/
Natalizumab
/
Immunologic Factors
/
Multiple Sclerosis
Type of study:
Observational_studies
/
Prognostic_studies
Limits:
Adolescent
/
Child
/
Female
/
Humans
/
Male
Language:
En
Journal:
Mult Scler
Journal subject:
NEUROLOGIA
Year:
2019
Document type:
Article
Affiliation country:
Alemania